CP-866087 - An Overview

CP-866087 - An Overview

Blog Article

cobicistat will raise the amount or impact of bortezomib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.

elvitegravir/cobicistat/emtricitabine/tenofovir DF improves levels of bortezomib by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

The E book of Genesis notes that the primary people ended up a couple, Adam and Eve. A person may well identify this as currently being necessary for replica and multiplication in the human race.

lorlatinib will lessen the extent or influence of bortezomib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.

This medication could be prescribed for other employs; talk to your doctor or pharmacist for more information.

itraconazole will increase the degree or influence of bortezomib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.

ceritinib will increase the degree or impact of bortezomib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.

  The drug is administered parenterally and requires near checking through the nursing staff. Moreover examining the CBC, the liver operate involves assessment. Before beginning the drug, a baseline chest X-ray is suggested.

anastrozole will increase the level or effect of bortezomib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Not known.

Drug interactions may well adjust how your drugs perform or improve your danger for serious side effects. This doc won't incorporate all achievable drug interactions.

You'll want to notify your doctor the way you are emotion throughout your remedy. Your health practitioner may perhaps stop your therapy for quite a while or minimize your dose of bortezomib if you encounter Uncomfortable side effects of your medication.

apalutamide will minimize the extent or influence of bortezomib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Prevent or Use Alternate Drug. Coadministration AXL-IN-13 of apalutamide, a solid CYP3A4 inducer, with medicines which might be CYP3A4 substrates may lead to decreased publicity to these drugs.

cenobamate will raise the amount or outcome of bortezomib by affecting hepatic enzyme CYP2C19 metabolism. Modify Therapy/Keep an eye on Intently. Take into account a dose reduction of CYP2C19 substrates, as clinically suitable, when applied concomitantly with cenobamate.

crizotinib boosts amounts of bortezomib by affecting Bortezomib hepatic/intestinal Lp-PLA2-IN-1 enzyme CYP3A4 metabolism. Use Caution/Monitor. Dose reduction can be required for coadministered prescription drugs which might be predominantly metabolized by CYP3A.